Abilify Uses

The treatment of bipolar disorder, major depression, and schizophrenia are the primary uses for Abilify. Occasionally, the medication can also be used "off-label" to treat other conditions. Among these possible off-label uses are the treatment of behavioral problems in elderly people with dementia and the treatment of other behavior problems.

Abilify Medication

What Is Abilify Used For?

Abilify^® (aripiprazole) is a prescription medicine known as an "atypical antipsychotic" that has been licensed to treat the following conditions:

Schizophrenia
Bipolar disorder
Major depression (when antidepressants are not adequate, to be used along with antidepressants).

Using Abilify for Schizophrenia

Schizophrenia is one of the most confusing and disabling mental illnesses. It is a group of mental disorders that involve abnormal thinking. Although the causes of schizophrenia are not fully understood, it is currently thought that genetics and environmental factors play an important role in developing the illness.

Depending on the type of schizophrenia (see Types of Schizophrenia), symptoms may include the following:

Hallucinations
Delusions
Thought disorders
Disorders of movement
Flat affect (immobile facial expression, monotonous voice)
Lack of pleasure in everyday life
A diminished ability to initiate and sustain planned activity
Speaking infrequently, even when forced to interact
Poor executive functioning (the ability to absorb and interpret information and make decisions based on that information)
An inability to stay focused
Problems with working memory (the ability to keep recently-learned information in the mind and use it right away).

Although psychotherapy may be helpful for schizophrenia (see Psychosocial Therapy for Schizophrenics), medication is often essential to schizophrenia treatment. Abilify can help improve the symptoms of schizophrenia. It also helps to prevent schizophrenia relapses (worsening of schizophrenia). However, Abilify is not a cure for schizophrenia.

(Abilify Uses Continued: Page 2)